A Phase 1b, Proof of Mechanism, Open-label Study of RO7070179, a Hypoxia-inducible Factor 1a (HIF1A) mRNA Antagonist in Adult Subjects With Hepatocellular Carcinoma (HCC)
Phase of Trial: Phase I
Latest Information Update: 19 Feb 2018
At a glance
- Drugs RG 6061 (Primary)
- Indications Liver cancer
- Focus Proof of concept; Therapeutic Use
- Sponsors Roche
- 13 Feb 2018 Status changed from active, no longer recruiting to completed.
- 14 Dec 2017 Planned End Date changed from 17 Nov 2017 to 31 Jan 2018.
- 14 Dec 2017 Planned primary completion date changed from 17 Nov 2017 to 31 Jan 2018.